Pfizer CEO open to big buyout deals

In an interview with the Financial Times, Pfizer CEO Jeff Kindler said the company is willing to acquire a large rival drugs company to improve its financial health, in a move that could trigger a fresh round of mergers within the sector. "The real goal is to grow revenues...We are open to opportunities and constantly looking at those which are big, small and in between," Kindler said in an interview. Pfizer is bracing itself to the expiration of Lipitor's patent protection in 2011; a major deal could help the company fill the $13-billion-a-year void the drug's patent expiration will cause. Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.